Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

85 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
Yuan R, Venitz J. Yuan R, et al. Among authors: venitz j. Int J Clin Pharmacol Ther. 2000 May;38(5):245-53. doi: 10.5414/cpp38245. Int J Clin Pharmacol Ther. 2000. PMID: 10839468 Clinical Trial.
Effect of uptake transporters OAT3 and OATP1B1 and efflux transporter MRP2 on the pharmacokinetics of eluxadoline.
Davenport JM, Covington P, Bonifacio L, McIntyre G, Venitz J. Davenport JM, et al. Among authors: venitz j. J Clin Pharmacol. 2015 May;55(5):534-42. doi: 10.1002/jcph.442. Epub 2015 Jan 14. J Clin Pharmacol. 2015. PMID: 25491493 Free PMC article. Clinical Trial.
The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies.
Brophy DF, Carr ME Jr, Martin EJ, Venitz J, Gehr TW. Brophy DF, et al. Among authors: venitz j. J Clin Pharmacol. 2006 Aug;46(8):887-94. doi: 10.1177/0091270006289975. J Clin Pharmacol. 2006. PMID: 16855073 Clinical Trial.
Evaluation of truncated areas in the assessment of bioequivalence of immediate release formulations of drugs with long half-lives and of Cmax with different dissolution rates.
Sathe P, Venitz J, Lesko L. Sathe P, et al. Among authors: venitz j. Pharm Res. 1999 Jun;16(6):939-43. doi: 10.1023/a:1018898624643. Pharm Res. 1999. PMID: 10397617
Transient kinetic and dynamic interactions between verapamil and dofetilide, a class III antiarrhythmic.
Johnson BF, Cheng SL, Venitz J. Johnson BF, et al. Among authors: venitz j. J Clin Pharmacol. 2001 Nov;41(11):1248-56. doi: 10.1177/00912700122012805. J Clin Pharmacol. 2001. PMID: 11697758 Clinical Trial.
Population pharmacokinetic analysis of sorafenib in patients with solid tumours.
Jain L, Woo S, Gardner ER, Dahut WL, Kohn EC, Kummar S, Mould DR, Giaccone G, Yarchoan R, Venitz J, Figg WD. Jain L, et al. Among authors: venitz j. Br J Clin Pharmacol. 2011 Aug;72(2):294-305. doi: 10.1111/j.1365-2125.2011.03963.x. Br J Clin Pharmacol. 2011. PMID: 21392074 Free PMC article.
Plasma protein binding of the investigational anticancer agent 2-methoxyestradiol.
Lakhani N, Sparreboom A, Venitz J, Dahut WL, Figg WD. Lakhani N, et al. Among authors: venitz j. Anticancer Drugs. 2006 Sep;17(8):977-83. doi: 10.1097/01.cad.0000224447.08706.92. Anticancer Drugs. 2006. PMID: 16940808
Factors involved in the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancer: clinical and experimental studies.
Rudek MA, Venitz J, Ando Y, Reed E, Pluda JM, Figg WD. Rudek MA, et al. Among authors: venitz j. J Clin Pharmacol. 2003 Oct;43(10):1124-35. doi: 10.1177/0091270003256675. J Clin Pharmacol. 2003. PMID: 14517195
Interspecies differences in plasma protein binding of MS-275, a novel histone deacetylase inhibitor.
Acharya MR, Sparreboom A, Sausville EA, Conley BA, Doroshow JH, Venitz J, Figg WD. Acharya MR, et al. Among authors: venitz j. Cancer Chemother Pharmacol. 2006 Feb;57(3):275-81. doi: 10.1007/s00280-005-0058-8. Epub 2005 Jul 19. Cancer Chemother Pharmacol. 2006. PMID: 16028097
Pharmacokinetic/pharmacodynamic modeling in drug research and development.
Derendorf H, Lesko LJ, Chaikin P, Colburn WA, Lee P, Miller R, Powell R, Rhodes G, Stanski D, Venitz J. Derendorf H, et al. Among authors: venitz j. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1399-418. J Clin Pharmacol. 2000. PMID: 11185661 Review.
85 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page